Cancers,
Год журнала:
2024,
Номер
16(11), С. 1953 - 1953
Опубликована: Май 21, 2024
In
this
study,
we
investigated
the
outcomes
and
factors
influencing
treatment
efficacy
in
93
patients
with
limited
disease
small
cell
lung
cancer
(LD-SCLC),
a
median
age
of
64
years.
We
focused
on
impact
chemotherapy
regimens,
prophylactic
cranial
irradiation
(PCI),
patient-related
variables.
The
follow-up
for
OS
was
17.3
months.
observed
statistically
significant
difference
PFS
between
LD-SCLC
treated
cisplatin
etoposide
(EP)
those
carboplatin
(CP)
(PFS:
EP
13.63
months
vs.
CP
6.54
months,
p
<
0.01).
Patients
had
better
overall
survival
(OS)
than
CP-treated
(OS:
26.9
16.16
Concomitant
associated
improved
(p
=
0.003)
0.002).
receiving
PCI
showed
superior
0.05)
trend
towards
0.057).
Female
gender
0.025).
Most
an
ECOG
performance
status
0
(71%).
This
real-world
study
underscores
importance
multidisciplinary
management,
emphasizing
roles
chemotherapy,
radiotherapy,
PCI.
These
findings
inform
personalized
strategies
emphasize
need
prospective
trials
to
validate
these
results
optimize
treatment.
Biomaterials Advances,
Год журнала:
2024,
Номер
165, С. 213998 - 213998
Опубликована: Авг. 19, 2024
This
review
discusses
the
relationship
between
inflammation
and
cancer
initiation
progression,
which
has
prompted
research
into
anti-inflammatory
approaches
for
prevention
treatment.
Specifically,
it
focuses
on
use
of
inflammation-reducing
agents
to
enhance
effectiveness
tumor
treatment
methods.
These
are
combined
with
platinum(II)-based
antitumor
drugs
create
multifunctional
platinum(IV)
prodrugs,
allowing
simultaneous
delivery
cells
in
a
specific
ratio.
Once
inside
subjected
intracellular
reduction,
both
components
can
act
parallel
through
distinct
pathways.
Motivated
by
objective
reducing
systemic
toxicity
associated
contemporary
chemotherapy,
aim
leveraging
passive
enhanced
permeability
retention
effect
exhibited
nanostructured
materials
improve
their
accumulation
within
tissues,
complexes
have
been
efficiently
loaded
mesoporous
silica
SBA-15
material.
The
resulting
capable
providing
controlled
release
conjugates
when
simulated
plasma
conditions.
feature
suggests
potential
extended
circulation
body
vivo,
minimal
premature
drug
before
reaching
intended
target
site.
primary
emphasis
this
is
that
integrates
these
two
develop
chemotherapeutic
treatments
more
efficient
less
harmful.
Plants,
Год журнала:
2024,
Номер
13(22), С. 3136 - 3136
Опубликована: Ноя. 7, 2024
The
study
aimed
to
investigate
the
protective
effects
of
chokeberry
fruit
products
and
by-products
against
cisplatin-induced
acute
nephrotoxicity
in
rats.
Potential
mechanisms
involving
oxidative
stress
inflammatory
responses
were
examined
through
biochemical
histopathological
analyses
kidney
tissue.
Chokeberry
waste,
along
with
whole
extract
juice,
was
evaluated
as
a
potential
raw
material
for
pharmaceutical
use.
chemical
composition
juice
extracts
analyzed
using
spectrophotometry
HPLC.
Rats
treated
preparations
via
intragastric
tube
ten
days,
single
intraperitoneal
dose
cisplatin
(8
mg/kg
BW)
administered
on
third
day.
Post-sacrifice,
plasma
samples
markers,
stress,
markers.
Kidneys
removed
analysis.
Cisplatin-induced
confirmed
by
elevated
creatinine
blood
urea
nitrogen
levels.
Additionally,
lipid
peroxidation
significantly
elevated,
while
reduced
glutathione
catalase
activity
reduced.
Pro-inflammatory
mediators
IL-1
It
is
well-established
that
oxaliplatin,
one
of
the
three
Pt(II)
anticancer
drugs
approved
worldwide,
and
phenanthriplatin,
an
important
preclinical
monofunctional
drug,
possess
a
different
mode
action
to
cisplatin
carboplatin,
namely
induction
nucleolar
stress.
The
exact
mechanisms
lead
Pt-induced
stress
are
however
still
poorly
understood.
As
such,
studies
aimed
at
better
understanding
biological
targets
both
oxaliplatin
phenanthriplatin
urgently
needed
expand
our
guide
future
design
Pt
chemotherapeutics.
One
approach
which
has
seen
great
success
in
past,
use
Pt-click
complexes
study
drugs.
Herein,
we
report
synthesis
characterization
first
examples
click-capable
complexes.
Furthermore,
through
monitoring
relocalization
proteins
DNA
damage
repair
biomarker
γH2AX,
by
investigating
their
vitro
cytotoxicity
show
these
successfully
mimic
cellular
responses
observed
for
treatment
same
experiments.
derivatives
described
here
existing
library
Significantly
they
suitable
studying
further
elucidating
Cancers,
Год журнала:
2024,
Номер
16(23), С. 4078 - 4078
Опубликована: Дек. 5, 2024
Cisplatin-based
chemotherapy
has
long
been
the
standard
first-line
(1L)
treatment
for
metastatic
urothelial
carcinoma
(mUC).
However,
up
to
50%
of
patients
with
mUC
may
be
ineligible
cisplatin
owing
comorbidities,
necessitating
alternative
primary
options.
Immune
checkpoint
inhibitors
(ICIs)
have
emerged
as
a
vital
those
unable
receive
cisplatin.
Nevertheless,
prognosis
advanced
UC
remains
dire
and
challenges
persist
in
optimizing
1L
therapy.
Recent
medical
advancements
redirected
attention
towards
innovative
drug
combinations
mUC.
The
combination
enfortumab
vedotin
(EV)
pembrolizumab
shown
significantly
improved
overall
progression-free
survival
rates
compared
alone.
This
can
used
who
are
cisplatin-ineligible
or
require
alternatives
chemotherapy.
While
platinum-based
continues
essential
many
patients,
approval
EV
treatments
signifies
major
breakthrough
cancer
care.
These
therapies
offer
enhanced
outcomes
terms
response
highlight
increasing
relevance
ICI-containing
regimens
frontline
review
provides
an
exhaustive
overview
current
landscape
explores
new
therapeutic
strategies,
aim
facilitating
clinical
decision-making
guiding
strategies
Cancers,
Год журнала:
2024,
Номер
16(11), С. 1953 - 1953
Опубликована: Май 21, 2024
In
this
study,
we
investigated
the
outcomes
and
factors
influencing
treatment
efficacy
in
93
patients
with
limited
disease
small
cell
lung
cancer
(LD-SCLC),
a
median
age
of
64
years.
We
focused
on
impact
chemotherapy
regimens,
prophylactic
cranial
irradiation
(PCI),
patient-related
variables.
The
follow-up
for
OS
was
17.3
months.
observed
statistically
significant
difference
PFS
between
LD-SCLC
treated
cisplatin
etoposide
(EP)
those
carboplatin
(CP)
(PFS:
EP
13.63
months
vs.
CP
6.54
months,
p
<
0.01).
Patients
had
better
overall
survival
(OS)
than
CP-treated
(OS:
26.9
16.16
Concomitant
associated
improved
(p
=
0.003)
0.002).
receiving
PCI
showed
superior
0.05)
trend
towards
0.057).
Female
gender
0.025).
Most
an
ECOG
performance
status
0
(71%).
This
real-world
study
underscores
importance
multidisciplinary
management,
emphasizing
roles
chemotherapy,
radiotherapy,
PCI.
These
findings
inform
personalized
strategies
emphasize
need
prospective
trials
to
validate
these
results
optimize
treatment.
